Literature DB >> 12196260

Morphological changes in the sciatic nerve of diabetic rats treated with low molecular weight heparin OP 2123/parnaparin.

M Artico1, R Massa, D Cavallotti, S Franchitto, C Cavallotti.   

Abstract

This study points out the early alterations that affect the sciatic nerve of rats with experimentally induced diabetes. It emphasizes the advantages deriving from treatment with low molecular weight heparin (LMWH) OP 2123/parnaparin and correlates these findings with observations emerging from a review of the relevant literature. In fact, the number and diameter of the capillaries within the sciatic nerve of diabetic rats appear to be increased consistent with a microangiopathy (the main characteristic of which is the fragility of new vessels), that is related to the evolution of diabetes in humans and animals. Our results suggest a possible therapeutic role for OP 2123/parnaparin in both diabetic neuropathy and microangiopathy, frequent complications of diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12196260     DOI: 10.1046/j.1439-0264.2002.00373.x

Source DB:  PubMed          Journal:  Anat Histol Embryol        ISSN: 0340-2096            Impact factor:   1.114


  3 in total

Review 1.  Emerging therapy for diabetic neuropathy: cell therapy targeting vessels and nerves.

Authors:  Hyongbum Kim; Julie J Kim; Young-sup Yoon
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2012-06       Impact factor: 2.895

2.  Endoneurial microvascular pathology in feline diabetic neuropathy.

Authors:  Jeannelyn S Estrella; Richard N Nelson; B K Sturges; Karen M Vernau; D Collette Williams; Richard A LeCouteur; G Diane Shelton; Andrew P Mizisin
Journal:  Microvasc Res       Date:  2007-12-23       Impact factor: 3.514

3.  The Effect of Co-administration of 4-Methylcatechol and Progesterone on Sciatic Nerve Function and Neurohistological Alterations in Streptozotocin-Induced Diabetic Neuropathy in Rats.

Authors:  Hamidreza Sameni; Marzieh Panahi
Journal:  Cell J       Date:  2011-04-21       Impact factor: 2.479

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.